Loading
Adaptimmune
Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.
Overview
Adaptimmune, based in Abingdon and Philadelphia, developed Tecelra, or afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, and sold its US rights to US WorldMeds in 2025 amid financial distress. Afami-cel targets MAGE-A4 and was proved in SPEARHEAD-1 in synovial sarcoma, letetresgene autoleucel targets NY-ESO-1, and uza-cel, its PRAME programme, was sold. OnCo links it to sarcomas, to the afami-cel drug record and to the SPEARHEAD-1 papers. Whether a scientifically successful cell therapy can survive commercially in a rare cancer is the question its history answers, and the answer here was no. Afamitresgene autoleucel has its own page.
Headquarters
Abingdon / Philadelphia, GB
Scorecard
All companies#247of 1245 companies, score 20
- approved products +6
- targets +4
- modalities +2
- regions +1
- 24-month regulatory events +4
- registry trials +3
1 approved, 0 in phase 3, 0 earlier, 2 targets, 2 registry studies. Formula on the scorecards page.
Type
Website
Products
1ApprovedTCR-T (MAGE-A4)
Afamitresgene autoleucel · Tecelra
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
Key papers
1Connected
5Similar pages
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- PersonSandra P. D'Angelo
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- TreatmentLetetresgene autoleucel
Shares IGNYTE-ESO, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- TrialSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- TargetMAGE-A4
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- CompanyUS WorldMeds
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- PersonJean-Yves Blay
Shares SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
- TermHLA-A*02:01 restriction
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
adaptimmune.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-27 · Jude Gomila · Say what the cancer does, not how to feel about it · diff · file · history
Sourced, not expert-reviewed